000 | 01312 a2200325 4500 | ||
---|---|---|---|
005 | 20250515230041.0 | ||
264 | 0 | _c20100727 | |
008 | 201007s 0 0 eng d | ||
022 | _a1535-5667 | ||
024 | 7 |
_a10.2967/jnumed.109.073445 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aSlifstein, Mark | |
245 | 0 | 0 |
_aWhen reversible ligands do not reverse, and other modelers' dilemmas. _h[electronic resource] |
260 |
_bJournal of nuclear medicine : official publication, Society of Nuclear Medicine _cJul 2010 |
||
300 |
_a1005-8 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Comment | ||
650 | 0 | 4 |
_aBenzazepines _xchemistry |
650 | 0 | 4 | _aLigands |
650 | 0 | 4 | _aModels, Structural |
650 | 0 | 4 |
_aNervous System _xdiagnostic imaging |
650 | 0 | 4 |
_aNiacinamide _xanalogs & derivatives |
650 | 0 | 4 |
_aPositron-Emission Tomography _xtrends |
650 | 0 | 4 |
_aRadiopharmaceuticals _xchemistry |
650 | 0 | 4 |
_aReceptors, Drug _xmetabolism |
650 | 0 | 4 | _aReceptors, Histamine H3 |
650 | 0 | 4 | _aReference Standards |
650 | 0 | 4 | _aTomography, Emission-Computed, Single-Photon |
773 | 0 |
_tJournal of nuclear medicine : official publication, Society of Nuclear Medicine _gvol. 51 _gno. 7 _gp. 1005-8 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.2967/jnumed.109.073445 _zAvailable from publisher's website |
999 |
_c19903839 _d19903839 |